期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
N-糖苷酶基因在脑膜炎败血伊丽莎白金菌临床分离株中的分布 被引量:2
1
作者 李蒙 孙桂芹 +4 位作者 陈菁 李天胜 王蕾 策力木格 陈力 《微生物与感染》 2014年第4期224-229,共6页
N‐糖苷酶(PNGase)是真核生物中的常见酶,但在原核生物中极为罕见,目前仅报道在脑膜炎败血伊丽莎白金菌(EM)中存在。本文旨在检测 PNGase基因在EM临床分离株中的分布,为该菌的亚型分类及快速核酸分子检测提供依据,为研究PNGase... N‐糖苷酶(PNGase)是真核生物中的常见酶,但在原核生物中极为罕见,目前仅报道在脑膜炎败血伊丽莎白金菌(EM)中存在。本文旨在检测 PNGase基因在EM临床分离株中的分布,为该菌的亚型分类及快速核酸分子检测提供依据,为研究PNGase在原核生物中的生物学功能奠定基础。于2010年7月~2012年12月收集浙江省3家三级甲等医院的65株EM临床分离株,提取细菌基因组 DNA ,利用16 S rRNA细菌通用引物、PNGase F和PNGase F‐Ⅱ特异性引物,进行组合聚合酶链反应(PCR)。阳性扩增产物测序后与美国国立生物技术信息中心(NCBI)数据库中已知EM序列比对确认。结果显示,PNGase阳性菌64株,总阳性率为98.5%;PNGase F和PNGase F‐Ⅱ共阳性菌39株,共阳性率为60.0%。 PNGase F阳性菌41株,阳性率为63.1%;PNGase F‐Ⅱ阳性菌62株,阳性率为95.4%,PNGase F‐Ⅱ阳性率高于 PNGase F (配对χ^2检验, P<0.01),提示 PNGase可能对EM具有重要的生物学意义。结果还表明,本研究建立的组合PCR可应用于E M菌株中 PN G ase基因分型。 展开更多
关键词 脑膜炎败血伊丽莎白金菌 聚合酶链反应 N-糖苷酶F-Ⅱ Peptide:n-glycanase F-Ⅱ
下载PDF
Targeted protein editing technique in living mammalian cells by peptide-fused PNGase
2
作者 Min Wu Guijie Bai +3 位作者 Ziyi Zhang Haixia Xiao Wenliang Sun Chaoguang Tian 《hLife》 2024年第11期576-591,共16页
Various precise gene editing techniques at the DNA/RNA level,driven by clustered regularly interspaced short palindrome repeats(CRISPR)/CRISPR-associated protein 9(Cas9)technology,have gained significant prominence.Ye... Various precise gene editing techniques at the DNA/RNA level,driven by clustered regularly interspaced short palindrome repeats(CRISPR)/CRISPR-associated protein 9(Cas9)technology,have gained significant prominence.Yet,research on targeted protein editing techniques remains limited.Only a few attempts have been made,including the use of specific proteases and de-O-glycosylating enzymes as editing enzymes.Here,we propose direct editing of Nglycosylated proteins using de-N-glycosylating enzymes to modify N-glycosylation and simultaneously alter the relevant asparagine residue to aspartate in living cells.Selective protein deglycosylation editors were developed by fusing high-affinity protein-targeting peptides with active peptide:N-glycanases(PNGases).Three crucial cell membrane proteins,programmed cell death protein-1(PD-1),programmed cell death-1 ligand 1(PD-L1),and severe acute respiratory syndrome coronavirus-2(SARS-CoV-2)spike protein,were chosen to be tested as a proof of concept.N-linked glycans were removed,and the relevant sites were converted from Asn to Asp in living mammalian cells,destabilizing target proteins and accelerating their degradation.Further investigation focused on SARS-CoV-2 spike protein deglycosylation editing.The collaboration of LCB1-PNGase F(PNGF)effectively reduced syncytia formation,inhibited pseudovirus packaging,and significantly hindered virus entry into host cells,which provides insights for coronavirus disease 2019(COVID-19)treatment.This tool enables editing protein sequences post-de-N-glycosylation in living human cells,shedding light on protein N-glycosylation functions,and Asn to Asp editing in organisms.It also offers the potential for developing protein degradation technologies. 展开更多
关键词 N-glycosylated proteins peptide:n-glycanase(PNGase) protein-targeting peptides DEGLYCOSYLATION protein sequence editing protein degradation
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部